Basecamp Research lands $140M Series C to test AI-designed drugs

What's the deal? Basecamp Research has raised $140 million in a Series C round backed by Menlo Ventures' Anthology FundDealroom has a profile for this one. Try Dealroom → and Nvidia. The AI startup also unveiled a six-program pipeline that will put its technology to the test.

What's the endgame? Founded in 2019, Basecamp Research set out to build a massive genetic database by gathering genetic data. It now aims to use that foundation to advance AI-designed drugs.

Why now? The new financing moves the company beyond data collection and into drug programs, a shift that requires demonstrating its AI can deliver on the science.

The signal: The round lands in the 94th percentile among all-time Series C deals for UK health startups, a sign of investor conviction in AI-driven drug discovery. Backing from Menlo Ventures' Anthology Fund and Nvidia underscores how AI infrastructure players are betting on the sector.

Read more: endpoints.news, genengnews.com, prnewswire.com

Image credit: Basecamp Research